| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 6.99 | 22.6% | 22.4% |
| Total Income | 6.99 | 22.6% | 22.4% |
| Expenditure | 13.27 | 6.0% | 5.0% |
| PBT | -6.64 | 25.3% | 17.1% |
| Net Profit | -6.65 | 25.0% | 17.3% |
| OPM | -89.84% | 33.59pp | 34.80pp |
| NPM | -95.15% | 36.19pp | 32.24pp |
| EPS | -0.62 | 8.8% | 36.7% |
Biofrontera Inc. Reports Q3 2025 Results: Revenues $7.0 Million
04 May 2026 · 4 May, 7:26 am
Summary
Biofrontera Inc. reported financial results for the third quarter and nine months ended September 30, 2025. Revenues for the first nine months of 2025 were $24.6 million, slightly lower than the $24.8 million reported for the same period in 2024. Third quarter revenues were $7.0 million, down from $9.0 million in the third quarter of 2024, due to advanced purchases ahead of a price increase. The company anticipates substantial fourth quarter and year-over-year annual revenue growth. Biofrontera closed the purchase of all Ameluz and RhodoLED US Assets from Biofrontera AG.
Key Highlights
- 1
Revenues for the first nine months of 2025 were stable at $24.6 million compared to $24.8 million for the same period in 2024.
- 2
Third quarter 2025 revenues were $7.0 million, compared to $9.0 million in the third quarter of 2024.
- 3
Operating expenses decreased 5% year over year in the third quarter of 2025 compared to the third quarter of 2024.
- 4
Biofrontera closed the purchase of all Ameluz and RhodoLED US Assets from Biofrontera AG, reducing the payment rate to 12%–15% of U.S. net sales from 25%–35%.
- 5
The company received the final $2.5 million of $11 million financing led by existing investors in October.
- 6
Biofrontera announced the divestiture of its Xepi antibiotic cream to Pelthos Pharmaceuticals for $3 million at closing, $1 million upon commercial availability, and up to $6 million in milestone payments.
Management Comments
Hermann Luebbert
“We remain on track to achieve our full-year sales objectives, supported by growing demand for our Ameluz-PDT treatment. The revenue decline in Q3 revenues was expected; with stable revenues for the first 9 months without the effect of last year’s October 1 price increase, we are well positioned going into the 4th quarter which is typically a strong quarter for us. The impact related to the 2024 price increase has begun to normalize in recent weeks, and we anticipate substantial fourth quarter and year over year annual revenue growth. Our revamped commercial approach, centered on a more focused and data driven sales strategy as well as a refined customer segmentation, is proving effective. We continue to educate both providers and patients on the clinical benefits of Ameluz and PDT with Red Light leading to a significant expansion of the installed base of RhodoLED lamps. This supports recurring, high-margin sales of Ameluz gel. In addition to the current use of Ameluz treating pre-cancerous skin lesions on the face and scalp, we are very encouraged about the potential of our almost completed clinical studies to gain FDA approval for the use of Ameluz to treat AK on the entire body, and the potential extension to be the first FDA approved PDT treatment for superficial basal cell carcinoma and acne vulgaris. Our recently completed agreement with Biofrontera AG represents a truly transformative milestone for the Company. By acquiring all U.S. rights, approvals, and patents for Ameluz and the RhodoLED lamps, we now have full control over our most important assets, from production to commercialization. This transaction is expected to significantly enhance our gross margins and strengthen our long-term profitability. The new royalty structure of 12% when U.S. Ameluz revenue is below $65 million and 15% when it exceeds that threshold, replaces the prior transfer-pricing model of 25% to 35%, creating meaningful financial leverage as we continue to grow the Ameluz brand in the U.S. market. As part of this transaction, we also secured an $11 million investment from our well-established healthcare-focused institutional investors, $2.5 million of which was received after the end of the reporting period. Combined with the recent addition of the proceeds from divesting the Xepi antibiotic cream, also added to the cash position after the period, our current liquidity positions us with a clear runway to sustained growth and profitability.”
Informational and educational content only. Not investment advice.